Identification of Niemann–Pick type C disease in the group of ataxias of unclear origin in adults
- Authors: Klyushnikov S.A.1, Proshlyakova T.Y.2, Baydakova G.V.2, Nuzhnyi E.P.1, Nikolaeva N.S.1, Goncharova Z.A.3, Fomina-Chertousova N.A.3, Degtereva E.V.3, Chernikova V.V.4, Gorshkova K.V.5, Artemova N.S.6, Shperling L.P.7, Antipova L.N.8, Tsyplugina O.Y.8, Ivanova I.L.9, Chepkasova L.V.10, Illarioshkin S.N.1
-
Affiliations:
- Research Center of Neurology
- Research Centre for Medical Genetics
- Rostov State Medical University
- Samara Regional Clinical Hospital named after V.D. Seredavin
- Central City Clinical Hospital N 23
- Clinic of South Ural State Medical University
- Regional Center for Extrapyramidal Disorders and Botulinum Therapy, City Clinical Hospital N 1
- Regional Clinical Hospital N 2
- Izhevsk State Medical Academy
- City Clinical Hospital N 9
- Issue: Vol 12, No 4 (2018)
- Pages: 37-46
- Section: Original articles
- Submitted: 12.12.2018
- Published: 12.12.2018
- URL: https://annaly-nevrologii.com/journal/pathID/article/view/547
- DOI: https://doi.org/10.25692/ACEN.2018.4.5
- ID: 547
Cite item
Full Text
Abstract
Introduction. Niemann–Pick type C disease (NPC) is a rare neurovisceral lysosomal storage disease with an autosomal recessie type of inheritance that develops as a result of abnormal intracellular transport of cholesterol and other lipids. The possibility of pathogenetic therapy makes it very important to screen the population and identify new cases of the disease.
Objective. Conducting biochemical and genetic screening in the group of adult patients with early-onset ataxia of unclear origin to detect new cases of NPC, with subsequent initiation of pathogenetic substrate reduction therapy and studies of clinical, genetic and biochemical characteristics the disease.
Materials and methods. Ninety-five persons (18–40 years of age), both males and females, from different regions of Russia suffering from primary ataxia of unknown origin, associated with other neurological symptoms and/or visceral and psychiatric disorders, were examined. Patients underwent neurological examination and neuropsychological testing. During biochemical screening, the concentrations of blood plasma oxysterols (cholestane-3β,5α,6β-triol and 7-ketocholesterol) and chitotriosidase were examined. The presence of pathogenic mutations in the NPC1 and NPC2 genes was detected by total sequencing of all exons of these genes.
Results. On biochemical screening, 3 patients were identified whose cholestane-3β,5α,6β-triol concentration and chitotriosidase activity were significantly higher than the reference norm, and 7-ketocholesterol concentration was either higher or at the level of the upper limit of the norm. On sequencing of the NPC1 gene, two unrelated patients (21-year-old woman and 37-year-old man) were found to carry 2 pathogenic compound heterozygous mutations each, and these findings confirm the diagnosis of NPC. The clinical picture was represented by a combination of neurological, psychiatric and visceral symptoms. In both patients, cerebellar ataxia was accompanied by dystonia and other extrapyramidal disorders, as well as vertical supranuclear gaze palsy, and bulbar and pseudobulbar symptoms. There were also affective disorders and progressive cognitive decline up to dementia of the frontal type. Both patients had ultrasound signs of isolated splenomegaly. The score for the NPC suspicion index was ≥200 points. Thus, in the studied group, NPC was detected in 2.1% of patients.
Conclusions. Biochemical screening of oxysterols and chitotriosidase of blood plasma is a quick and inexpensive method for biochemical diagnosis of NPC, the diagnostic value of which is unquestionable in the case of integrated assessment of the history of the disease, the clinical picture and the results of instrumental diagnostic exams. Adult patients with early-onset ataxia associated with visceral and psychiatric disorders are at risk group for having NPC. They should primarily be sent to screening biochemical studies, and, in case of positive results, to carry out mutation screening of NPC1 and NPC2 genes.
About the authors
Sergey A. Klyushnikov
Research Center of Neurology
Author for correspondence.
Email: sergeklyush@gmail.com
Россия, Moscow
Tatiana Yu. Proshlyakova
Research Centre for Medical Genetics
Email: sergeklyush@gmail.com
Россия, Moscow
Galina V. Baydakova
Research Centre for Medical Genetics
Email: sergeklyush@gmail.com
Россия, Moscow
Evgenii P. Nuzhnyi
Research Center of Neurology
Email: sergeklyush@gmail.com
Россия, Moscow
Natalya S. Nikolaeva
Research Center of Neurology
Email: sergeklyush@gmail.com
Россия, Moscow
Zoya A. Goncharova
Rostov State Medical University
Email: sergeklyush@gmail.com
Россия, Rostov-on-Don
Neonila A. Fomina-Chertousova
Rostov State Medical University
Email: sergeklyush@gmail.com
Россия, Rostov-on-Don
Elena V. Degtereva
Rostov State Medical University
Email: sergeklyush@gmail.com
Россия, Rostov-on-Don
Victoria V. Chernikova
Samara Regional Clinical Hospital named after V.D. Seredavin
Email: sergeklyush@gmail.com
Россия, Samara
Kristina V. Gorshkova
Central City Clinical Hospital N 23
Email: sergeklyush@gmail.com
Россия, Yekaterinburg
Natalya S. Artemova
Clinic of South Ural State Medical University
Email: sergeklyush@gmail.com
Россия, Chelyabinsk
Larisa P. Shperling
Regional Center for Extrapyramidal Disorders and Botulinum Therapy, City Clinical Hospital N 1
Email: sergeklyush@gmail.com
Россия, Novosibirsk
Lyudmila N. Antipova
Regional Clinical Hospital N 2
Email: sergeklyush@gmail.com
Россия, Krasnodar
Olga Yu. Tsyplugina
Regional Clinical Hospital N 2
Email: sergeklyush@gmail.com
Россия, Krasnodar
Irina L. Ivanova
Izhevsk State Medical Academy
Email: sergeklyush@gmail.com
Россия, Izhevsk
Lyubov V. Chepkasova
City Clinical Hospital N 9
Email: sergeklyush@gmail.com
Россия, Izhevsk
Sergey N. Illarioshkin
Research Center of Neurology
Email: sergeklyush@gmail.com
Россия, Moscow
References
- Liscum L. Niemann-Pick type C mutations cause lipid traffic jam. Traffic 2000; 1: 218–225. doi: 10.1034/j.1600-0854.2000.010304.x. PMID: 11208105.
- Patterson M.C., Vanier M.T., Suzuki K. et al. Niemann–Pick disease type C: a lipid trafficking disorder. In: Scriver C.R., Beaudet A.L., Sly W.S. et al. (eds.) The Metabolic and Molecular Bases of Inherited Disease. N.Y., 2001: 3611–3634.
- Pentchev P.G., Brady R.O., Blanchette-Mackie E.J. et al. The Niemann–Pick C lesion and its relationship to the intracellular distribution and utilization of LDL cholesterol. Biochim Biophys Acta 1994; 1225: 235–243. PMID: 8312368.
- Pentchev P.G., Comly M.E., Kruth H.S. et al. A defect in cholesterol esterification in Niemann–Pick disease (type C) patients. Proc Natl Acad Sci USA 1985; 82: 8247–8251. PMID: 3865225.
- Klyushnikov S.А. [Niemann–Pick disease type C – lysosomal pathology with impairment of intracellular lipid transport] Nervnye bolezni 2014; 1: 4–14. (In Russ.)
- Patterson M.C., Clayton P., Gissen P. et al. Recommendations for the detection and diagnosis of Niemann–Pick disease type C: An update. Neurol Clin Pract 2017; 7: 499–511. doi: 10.1212/CPJ.0000000000000399. PMID: 29431164.
- Vanier M.T. Phenotypic and genetic heterogeneity in Niemann–Pick disease type C: current knowledge and practical implications. Wien Klin Wochenschr 1997; 109: 68–73. PMID: 9060145.
- Vanier M.T. Niemann–Pick disease type C. Orphanet J Rare Dis 2010; 5: 16. doi: 10.1186/1750-1172-5-16. PMID: 20525256.
- Patterson M.C., Hendriksz C.J., Walterfang M. et al. Recommendations for the diagnosis and management of Niemann–Pick disease type C: an update. Mol Genet Metab 2012; 106: 330–344. doi: 10.1016/j.ymgme.2012.03.012. PMID: 22572546.
- Yanjanin N.M., Vélez J.I., Gropman A. et al. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 132–140. doi: 10.1002/ajmg.b.30969. PMID: 19415691.
- Mengel E., Klünemann H.H., Lourenço C.M. et al. Niemann–Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis 2013; 8: 166. doi: 10.1186/1750-1172-8-166. PMID: 24135395.
- Mikhailova S.V., Zakharova E.Yu. Bolezn' Nimana–Pika, tip C [Niemann–Pick disease, type C]. Moscow, 2012. 48 p. (In Russ.)
- Rudenskaya G.E., Bukina T.M., Zakharova E.Yu. [Niemann–Pick disease type C. Adult form with predominance of psychiatric disorders]. S.S. Korsakov Journal of Neurology and Psychiatry 2011; 111(7): 71–75. PMID: 21947076. (In Russ.)
- Klyushnikov S.А. [Niemann–Pick disease type C diagnostic algorithm]. Nervnye bolezni 2012; 4: 8–12. (In Russ.)
- Klyushnikov S.А., Smirnov O.R., Zakharova E.Yu. [Case of Niemann–Pick type C disease] Nevrologiya, neyropsikhiatriya, psikhosomatika 2013; 4: 43–48. doi: 10.14412/2074-2711-2013-2454. (In Russ.)
- Sayfullina E.V., Magzhanov R.V., Mardanova А.K. et al. [Clinical case of adult form of Niemann–Pick disease type C]. Nevrologiya, nejropsikhiatriya, psikhosomatika 2016; 8(3): 66–70. doi: 10.14412/2074-2711-2016-3-66-70 (In Russ.)
- Wijburg F.A., Sedel F., Pineda M. et al. Development of a suspicion index to aid diagnosis of Niemann–Pick disease type C. Neurology 2012; 78: 1560–1567. doi: 10.1212/WNL.0b013e3182563b82. PMID: 22517094.
- Hendriksz C.J., Pineda M., Fahey M. et al. The Niemann–Pick disease type C suspicion index: development of a new tool to aid diagnosis. J Rare Dis Diagn Ther 2015; 1: 1. doi: 10.21767/2380-7245.100011.
- Geberhiwot T., Moro A., Dardis A. et al. Consensus clinical management guidelines for Niemann–Pick disease type C. Orphanet J Rare Dis 2018; 13: 50. doi: 10.1186/s13023-018-0785-7. PMID: 29625568.
- Jiang X., Sidhu R., Porter F.D. et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann–Pick C1 disease from human plasma. J Lipid Res 2011; 52: 1435–1445. doi: 10.1194/jlr.D015735. PMID: 21518695.
- Proshlyakova T.Yu., Baydakova G.V., Bukina T.M. et al. [Biomarkers of Niemann–Pick disease type C] Meditsinskaya genetika 2015; 14(8): 3–6. (In Russ.)
- Welford R.W., Garzotti M., Lourenço C.M. et al. Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann–Pick disease type C in a retrospective study. PLoS One 2014; 9: e114669. doi: 10.1371/journal.pone.0114669. PMID: 25479233.
- Giese A.K., Mascher H., Grittner U. et al. A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease. Orphanet J Rare Dis 2015; 10: 78. doi: 10.1186/s13023-015-0274-1. PMID: 26082315.
- Jiang X., Sidhu R., Mydock-McGrane L. et al. Development of a bile acid-based newborn screen for Niemann–Pick disease type C. Sci Transl Med 2016; 8: 337ra63. doi: 10.1126/scitranslmed.aaf2326. PMID: 27147587.
- Mazzacuva F., Mills P., Mills K. et al. Identification of novel bile acids as biomarkers for the early diagnosis of Niemann–Pick C disease. FEBS Lett 2016; 590: 1651–1662. doi: 10.1002/1873-3468.12196. PMID: 27139891.
- Chien Y.H., Peng S.F., Yang C.C. et al. Long-term efficacy of miglustat in paediatric patients with Niemann–Pick disease type C. J Inherit Metab Dis 2013, 36: 129–137. doi: 10.1007/s10545-012-9479-9. PMID: 22476
- Fecarotta S., Romano A., Della Casa R. et al. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Orphanet J Rare Dis 2015; 10: 22. doi: 10.1186/s13023-015-0240-y. PMID: 25888393.
- Fecarotta S., Amitrano M., Romano A. et al. The videofluoroscopic swallowing study shows a sustained improvement of dysphagia in children with Niemann–Pick disease type C after therapy with miglustat. Am J Med Genet A 2011; 155A: 540–547. doi: 10.1002/ajmg.a.33847. PMID: 21344635.
- Galanaud D., Tourbah A., Lehericy S. et al. 24 month-treatment with miglustat of three patients with Niemann–Pick disease type C: follow up using brain spectroscopy. Mol Genet Metab 2009, 96: 55–58. doi: 10.1016/j.ymgme.2008.10.002. PMID: 19013089.
- Pineda M., Walterfang M., Patterson M.C. Miglustat in Niemann–Pick disease type C patients: a review. Orphanet J Rare Dis 2018; 13: 140. doi: 10.1186/s13023-018-0844-0. PMID: 30111334.
- Wraith J.E., Baumgartner M.R., Bembi B. et al. Recommendations on the diagnosis and management of Niemann–Pick disease type C. Mol Genet Metab 2009; 98: 152–165. doi: 10.1016/j.ymgme.2009.06.008. PMID: 19647672.
- Synofzik M., Harmuth F., Stampfer M. et al. NPC1 is enriched in unexplained early onset ataxia: a targeted high-throughput screening. J Neurol 2015; 262: 2557–2563. doi: 10.1007/s00415-015-7889-y. PMID: 26338816.
- Proshlyakova T.Yu. Molekulyarno-geneticheskaya i biokhimicheskaya kharakteristika bolezni Nimanna–Pika tip C u rossijskikh bol'nykh: diss. … cand. biol. sci. [Molecular genetics and biochemical characteristic of Niemann–Pick disease type C in Russian patients: Ph.D Thesis]. Moscow, 2015. 185 p. (In Russ.)
- Proshlyakova T.Yu., Baydakova G.V., Bukina T.M. et al. [Niemann–Pick disease type C diagnosis using biochemical biomarkers]. Rossiysky vestnik perinatologii i pediatrii 2016; 61(4): 202–203. (In Russ.)
- Proshlyakova T.Yu., Baydakova G.V., Kamenets E.А. et al. [Oxysterols in differential diagnosis of lysosomal storage diseases] Meditsinskaya genetika 2016; 15(12): 37–41. (In Russ.)
- Degtyareva А.V., Mikhaylova S.V., Zakharova E.Yu. et al. [New approaches for diagnosis of Niemann–Pick disease type C]. Meditsinskaya genetika 2018; 17(4): 16–24. doi: 10.25557/2073-7998.2018.04.16-24. (In Russ.)
- Schmitz-Hübsch T., Fimmers R., Rakowicz M. et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010; 74: 678–684. doi: 10.1212/WNL.0b013e3181d1a6c9. PMID: 20177122.
- Weyer A., Abele M., Schmitz-Hübsch T. et al. Reliability and validity of the Scale for the Assessment and Rating of Ataxia: a study in 64 ataxia patients. Mov Disord 2007; 22: 1633–1637. doi: 10.1002/mds.21544. PMID: 17516493.
- Pineda M., Perez-Poyato M., O’Callaghan M. et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: A case series. Mol Genet Metab 2010; 99: 358–366. doi: 10.1016/j.ymgme.2009.11.007. PMID: 20056559.
- Reunert J., Fobker M., Kannenberg F. et al. Rapid diagnosis of 83 patients with Niemann–Pick type C disease and related cholesterol transport disorders by cholestantriol screening. EBioMedicine 2016; 4: 170–175. doi: 10.1016/j.ebiom.2015.12.018. PMID: 26981555.
- Wassif C.A., Cross J.L., Iben J. et al. High incidence of unrecognized visceral/ neurological late-onset Niemann–Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med 2016; 18: 41–48. doi: 10.1038/gim.2015.25. PMID: 25764212.
- Received 03.07.2018